Andrea Coravos

Andrea Coravos

Auto-generated profile, based on publicly available information

Andrea Coravos

Digital Medicine Society (DiMe), Boston, MA USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2020 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
JGJennifer C. Goldsack
Jennifer C. Goldsack
ACAndrea Coravos
Andrea Coravos
JBJessie P. Bakker
Jessie P. Bakker
BBBrinnae Bent
Brinnae Bent
ADAriel V. Dowling
Ariel V. Dowling
Jessilyn DunnJessilyn Dunn
Jessilyn Dunn
Digital medicine is an interdisciplinary field, drawing together stakeholders with expertize in engineering, manufacturing, clinical science, data science, biostatistics, regulatory science, ethics, patient advocacy, and healthcare policy, to name a few. Although this diversity is undoubtedly valuable, it can lead to confusion regarding terminology and best practices. There are many instances, as we detail in this paper, where a single term is used by different groups to mean different things, as well as cases where multiple terms are used to describe essentially the same concept. Our intent is to clarify core terminology and best practices for the evaluation of Biometric Monitoring Technologies (BioMeTs), without unnecessarily introducing new terms. We focus on the evaluation of BioMeTs as fit-for-purpose for use in clinical trials. However, our intent is for this framework to be instructional to all users of digital measurement tools, regardless of setting or intended use. We propose and describe a three-component framework intended to provide a foundational evaluation framework for BioMeTs. This framework includes (1) verification, (2) analytical validation, and (3) clinical validation. We aim for this common vocabulary to enable more effective communication and collaboration, generate a common and meaningful evidence base for BioMeTs, and improve the accessibility of the digital medicine field.

11 March 2019 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
ACAndrea Coravos
Andrea Coravos
SKSean Khozin
Sean Khozin
KMKenneth D. Mandl
Kenneth D. Mandl
Biomarkers are physiologic, pathologic, or anatomic characteristics that are objectively measured and evaluated as an indicator of normal biologic processes, pathologic processes, or biological responses to therapeutic interventions. Recent advances in the development of mobile digitally connected technologies have led to the emergence of a new class of biomarkers measured across multiple layers of hardware and software. Quantified in ones and zeros, these “digital” biomarkers can support continuous measurements outside the physical confines of the clinical environment. The modular software–hardware combination of these products has created new opportunities for patient care and biomedical research, enabling remote monitoring and decentralized clinical trial designs. However, a systematic approach to assessing the quality and utility of digital biomarkers to ensure an appropriate balance between their safety and effectiveness is needed. This paper outlines key considerations for the development and evaluation of digital biomarkers, examining their role in clinical research and routine patient care.

9 May 2019 in Digital Biomarkers
Verified
Journal Article
Open access
PDF file
ACAndrea Coravos
Andrea Coravos
JGJennifer C. Goldsack
Jennifer C. Goldsack
DKDaniel R. Karlin
Daniel R. Karlin
CNCamille Nebeker
Camille Nebeker
EPEric Perakslis
Eric Perakslis
MEM. Kelley Erb
M. Kelley Erb
Technology is changing how we practice medicine. Sensors and wearables are getting smaller and cheaper, and algorithms are becoming powerful enough to predict medical outcomes. Yet despite rapid advances, healthcare lags behind other industries in truly putting these technologies to use. A major barrier to entry is the cross-disciplinary approach required to create such tools, requiring knowledge from many people across many fields. We aim to drive the field forward by unpacking that barrier, providing a brief introduction to core concepts and terms that define digital medicine. Specifically, we contrast “clinical research” versus routine “clinical care,” outlining the security, ethical, regulatory, and legal issues developers must consider as digital medicine products go to market. We classify types of digital measurements and how to use and validate these measures in different settings. To make this resource engaging and accessible, we have included illustrations and figures throughout that we hope readers will borrow from liberally. This primer is the first in a series that will accelerate the safe and effective advancement of the field of digital medicine.

23 April 2019 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
SKSean Khozin
Sean Khozin
ACAndrea Coravos
Andrea Coravos

3 April 2020 in npj Digital Medicine
Verified
Journal Article
Open access
CMCaroline Marra
Caroline Marra
JCJacqueline L. Chen
Jacqueline L. Chen
ACAndrea Coravos
Andrea Coravos
ASAriel D. Stern
Ariel D. Stern
Over recent years, the adoption of connected technologies has grown dramatically, with potential for improving health care delivery, research, and patient experience. Yet, little has been documented about the prevalence and use of connected digital products (e.g., products that capture physiological and behavioral metrics) in formal clinical research. Using 18 years of data from ClinicalTrials.gov, we document substantial growth in the use of connected digital products in clinical trials (~34% CAGR) and show that these products have been used across all phases of research and by a diverse group of trial sponsors. We identify four distinct use cases for how such connected products have been integrated within clinical trial design and suggest implications for various stakeholders engaging in clinical research.

13 March 2020 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
ACAndrea Coravos
Andrea Coravos
MDMegan Doerr
Megan Doerr
JGJennifer Goldsack
Jennifer Goldsack
CMChristine Manta
Christine Manta
MSMark Shervey
Mark Shervey
WWWilliam Wood
William Wood
This manuscript is focused on the use of connected sensor technologies, including wearables and other biosensors, for a wide range of health services, such as collecting digital endpoints in clinical trials and remotely monitoring patients in clinical care. The adoption of these technologies poses five risks that currently exceed our abilities to evaluate and secure these products: (1) validation, (2) security practices, (3) data rights and governance, (4) utility and usability; and (5) economic feasibility. In this manuscript we conduct a landscape analysis of emerging evaluation frameworks developed to better manage these risks, broadly in digital health. We then propose a framework specifically for connected sensor technologies. We provide a pragmatic guide for how to put this evaluation framework into practice, taking lessons from concepts in drug and nutrition labels to craft a connected sensor technology label.